The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

Siemens Healthineers announced today its Innovance Antithrombin assay has achieved FDA clearance for a new claim allowing it to be used as a companion diagnostic test for people receiving treatment ...

a cancer of the plasma cells. Another inherited blood disorder is haemophilia, which causes blood to not clot properly. The disorder mostly affects males; Queen Victoria’s male descendants ...

Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration's (FDA) approval of Qfitliatm (fitusiran), the sixth ...

The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, ...

Sanofi’s attempt to take on Roche with a ground-breaking approach to treating haemophilia has hit a setback ... halted a phase 2 trial in 2017 after a blood clot killed a patient but research ...

Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that enhance therapeutic efficacy across oncology, autoimmune disorders, and ra | ...

When this happens, immune cells make antibodies that bind to the clotting ... particularly high rates of blood-borne infections transmitted to hemophilia patients via certain medications in the 1980s.

When this happens, immune cells produce neutralizing antibodies ... includes most of the proteins needed for blood clotting. Fresh frozen plasma was considered a mainstay treatment for hemophilia A ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...